Form 4: USANA Legal Officer Sells Shares, Receives New Stock Units

USANA Health Sciences' Chief Legal Officer, Joshua Foukas, reported selling common stock while simultaneously being granted a significant number of restricted stock units.

Summary

• Joshua Foukas, Chief Legal Officer of USANA Health Sciences Inc. (USNA), reported transactions in a Form 4 filing.
• On February 20, 2026, Foukas disposed of 4,461 shares of USNA common stock at a price of $21.345 per share.
• Following this disposition, Foukas directly owns 0 shares of common stock.
• On February 19, 2026, Foukas was granted 36,662 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of USNA common stock.
• These newly granted RSUs will vest at 25% on each February 19th thereafter.
• After the RSU grant, Foukas beneficially owns 73,270 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale occurred, it was accompanied by a significant RSU grant, indicating continued long-term alignment with the company.

Positives

• Grant of 36,662 Restricted Stock Units (RSUs) to the Chief Legal Officer, aligning his interests with long-term company performance.
• The total beneficial ownership of derivative securities (RSUs) increased to 73,270, indicating continued significant equity interest.

Negatives

• Disposition of 4,461 shares of common stock by the Chief Legal Officer.
• Direct beneficial ownership of common stock is now 0 shares following the reported transaction.

Future Outlook

The newly granted Restricted Stock Units will vest at 25% on each February 19th thereafter, indicating a future incentive structure for the Chief Legal Officer.

Industry Context

StockSavvy.ai notes that insider transactions, such as the sale of common stock and the grant of restricted stock units, are common practices in executive compensation within the health and wellness industry. The grant of RSUs is a standard mechanism to align executive incentives with long-term shareholder value, while stock sales can be for personal financial planning or tax purposes.

Comparison to Industry Standards

• Executive compensation structures involving a mix of cash, stock options, and restricted stock units are standard across publicly traded companies, including those in the health and wellness sector.
• The vesting schedule of 25% annually is a common practice designed to retain executives and incentivize sustained performance. Specific comparable companies or projects are not detailed in this filing.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the Chief Legal Officer's interests with long-term shareholder value. The sale of common stock might be viewed neutrally as it's offset by new equity grants.

Next Steps

• The newly granted Restricted Stock Units will vest at 25% on each February 19th thereafter, starting from February 19, 2027.

Key Dates

Recommendation

The filing details routine insider transactions, including a sale of common stock and a grant of restricted stock units. This type of activity is common for executive compensation and personal financial planning and does not inherently suggest a change in the company's fundamental outlook or performance. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide sufficient information to warrant a change in investment thesis.

Keywords

USANA Health Sciences, USNA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Executive Compensation, Joshua Foukas, Chief Legal Officer